These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29954099)

  • 21. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
    Kim Y; Anderson JL; Lewin SR
    Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
    Covino DA; Desimio MG; Doria M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs.
    Sánchez-Duffhues G; Vo MQ; Pérez M; Calzado MA; Moreno S; Appendino G; Muñoz E
    Curr Drug Targets; 2011 Mar; 12(3):348-56. PubMed ID: 20955147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch.
    Venkatachari NJ; Zerbato JM; Jain S; Mancini AE; Chattopadhyay A; Sluis-Cremer N; Bar-Joseph Z; Ayyavoo V
    Retrovirology; 2015 Oct; 12():85. PubMed ID: 26438393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui.
    Wang P; Lu P; Qu X; Shen Y; Zeng H; Zhu X; Zhu Y; Li X; Wu H; Xu J; Lu H; Ma Z; Zhu H
    Sci Rep; 2017 Aug; 7(1):9451. PubMed ID: 28842560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal.
    Richard K; Schonhofer C; Giron LB; Rivera-Ortiz J; Read S; Kannan T; Kinloch NN; Shahid A; Feilcke R; Wappler S; Imming P; Harris M; Brumme ZL; Brockman MA; Mounzer K; Kossenkov AV; Abdel-Mohsen M; Andrae-Marobela K; Montaner LJ; Tietjen I
    J Biol Chem; 2020 Oct; 295(41):14084-14099. PubMed ID: 32788215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
    Reuse S; Calao M; Kabeya K; Guiguen A; Gatot JS; Quivy V; Vanhulle C; Lamine A; Vaira D; Demonte D; Martinelli V; Veithen E; Cherrier T; Avettand V; Poutrel S; Piette J; de Launoit Y; Moutschen M; Burny A; Rouzioux C; De Wit S; Herbein G; Rohr O; Collette Y; Lambotte O; Clumeck N; Van Lint C
    PLoS One; 2009 Jun; 4(6):e6093. PubMed ID: 19564922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell toxicity of HIV latency reversing agents.
    Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
    Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation.
    Larragoite ET; Nell RA; Martins LJ; Barrows LR; Planelles V; Spivak AM
    Biochem Pharmacol; 2022 Jan; 195():114844. PubMed ID: 34801521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency.
    Vargas B; Giacobbi NS; Sanyal A; Venkatachari NJ; Han F; Gupta P; Sluis-Cremer N
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.
    Matsuda K; Kobayakawa T; Tsuchiya K; Hattori SI; Nomura W; Gatanaga H; Yoshimura K; Oka S; Endo Y; Tamamura H; Mitsuya H; Maeda K
    J Biol Chem; 2019 Jan; 294(1):116-129. PubMed ID: 30413535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
    Hayashi T; Jean M; Huang H; Simpson S; Santoso NG; Zhu J
    Antiviral Res; 2017 Oct; 146():76-85. PubMed ID: 28842263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
    Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
    PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1.
    Lin J; Zhang X; Lu W; Xu X; Pan X; Liang T; Duan S; Chen Y; Li L; Liu S
    Biochem Pharmacol; 2018 Oct; 156():511-523. PubMed ID: 30170098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b.
    Liang T; Zhang X; Lai F; Lin J; Zhou C; Xu X; Tan X; Liu S; Li L
    Biochem Pharmacol; 2019 Jun; 164():237-251. PubMed ID: 30991051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.